Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.66M$3.66Mderived−9.3% vs Q4 2017 Net Income-$4.76M-$4.76MderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,332,000−31.5% Operating Incomederived-$4,749,000N/M Operating Cash Flowderived-$3,048,000N/M Free Cash Flowderived-$3,057,000N/M Margins · derivedGross margin36.4%−11.8 pt vs Q4 2017
Operating margin-129.9%−57.6 pt vs Q4 2017
Net margin-130.3%−69.8 pt vs Q4 2017
ended Mar 31, 2018 · filed Jun 26, 2018 · 87 d after period end